Palopegteriparatide
id:
palopegteriparatide-206-13570420
title:
Palopegteriparatide
text:
Palopegteriparatide, sold under the brand name Yorvipath, is a hormone replacement therapy used for the treatment of hypoparathyroidism. It is a transiently pegylated parathyroid hormone. It is a parathyroid hormone analog. Palopegteriparatide was approved for medical use in the European Union in November 2023, and in the United States in August 2024.
brand slug:
wiki
category slug:
encyclopedia
description:
Medication
original url:
https://en.wikipedia.org/wiki/Palopegteriparatide
date created:
2023-09-24T18:25:03Z
date modified:
2024-09-10T18:37:47Z
main entity:
{"identifier":"Q122981551","url":"https://www.wikidata.org/entity/Q122981551"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/2/26/Palopegteriparatide.svg","width":512,"height":186}
fields total:
13
integrity:
16